Skip to main content
Back
Watch Compare

Aprea Therapeutics, Inc.

Data quality: 83%
APRE
NASDAQ Manufacturing Chemicals
$0.94
▲ $0.00 (0.21%)
6 months return
—
Momentum
Neutral
ROE
-103.58%

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-103.58%
Below sector avg (-54.47%)
ROIC-81.10%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio5.20
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-0.65 | -1.39
Above sector avg (-1.49)
P/B Ratio0.76
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -12.91 M

Price History

Financial Trends

Analyst Price Target

3 analysts
Buy
+366.6%
upside to target
Current
$0.94
Consensus Target
$4.40
$1.20
Low
$7.00
High
Forecast
Forward P/E
-1.39
Forward EPS
-$0.66
Est. Revenue
1.07 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.23 · Rev Est: 0.0
Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$0.53 -$0.47 -$0.32 — —
Estimate -$0.71 -$0.10 -$0.36 -$0.23 -$0.24
Surprise +25.35% -370.00% +11.11% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -103.58% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -12.60 M
ROE -103.58% ROA -79.67%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12.91 M
ROIC -81.10% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 5.20
Debt / Equity N/A Current Ratio 5.20
Interest Coverage N/A Asset Turnover N/A
Working Capital 11.26 M Tangible Book Value 10.91 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0.65 · EV/EBITDA: N/A
P/E Ratio -0.65 Forward P/E -1.39
P/B Ratio 0.76 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 7.70 Fwd Earnings Yield N/A
FCF Yield -156.56%
Market Cap 8.25 M Enterprise Value -5.47 M

Per Share

EPS: -1.93 · FCF/Share: -1.13
EPS (Diluted TTM) -1.93 Revenue / Share N/A
FCF / Share -1.13 OCF / Share -1.13
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 102.46% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 102.46%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -12.60 M -12.96 M -14.29 M -112.66 M -37.13 M
EPS (Diluted) -1.93 -2.45 -3.95 -68.16 -1.74
Gross Profit — — — — —
Operating Income -13.23 M -14.32 M -15.47 M — —
EBITDA — — — — —
R&D Expenses — — — — 23.90 M
SG&A Expenses — — — — —
D&A 21,715.0 22,318.0 7,052.0 4,403.0 12,829.0
Interest Expense — — — — —
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15.93 M 23.98 M 22.65 M 30.16 M 56.82 M
Total Liabilities — — — 3.20 M 7.32 M
Shareholders' Equity 12.44 M 19.31 M 16.95 M 25.64 M 49.51 M
Total Debt — — — — —
Cash & Equivalents 14.60 M 22.85 M 21.61 M 28.79 M 53.08 M
Current Assets 15.56 M 23.58 M 22.52 M 30.15 M 56.58 M
Current Liabilities 2.76 M 3.36 M 4.39 M 3.20 M 7.32 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -0.7 -1.5
P/B 0.8 1.6
ROE % -103.6 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3